Federal Government Funding for Biomedical Research and NIH
This paper explores the federal government's role in funding biomedical and medical research, with a particular focus on the National Institutes of Health (NIH). It outlines the major achievements attributable to NIH-supported research, examines the distribution of funding between federal, nonprofit, and private sources, and addresses concerns about pharmaceutical companies benefiting disproportionately from government-funded discoveries. The paper also considers what would happen if federal research funding were significantly reduced, emphasizing the economic burden of illness, the rise of emerging infectious diseases, and the broader social benefits of sustained medical innovation.
- Introduction to Federal Government Funding: Overview of federal role in medical research
- NIH Achievements and Funding Distribution: NIH accomplishments and sector funding breakdown
- Concerns About Federal Government Funding: Pharmaceutical companies profiting from public research
- The Pharmaceutical Industry and Public Research: Patents, incentives, and government subsidization tensions
- Consequences of Reducing Federal Research Funding: Risks and costs of cutting NIH research budgets
- Conclusion: Case for sustained federal medical research investment
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Draws on specific statistics (e.g., NIH funding as 36% of biomedical research, illness costs equaling 31% of GDP) to ground abstract policy arguments in concrete data.
- Presents a balanced view by acknowledging both the achievements of federal funding and the legitimate criticisms about how private pharmaceutical companies exploit publicly funded research.
- Connects macroeconomic reasoning (cost-benefit analysis of NIH investment versus illness costs) to real-world public health outcomes.
Key academic technique demonstrated
The paper effectively uses a cost-benefit framework to evaluate federal research funding. By comparing the relatively modest NIH budget (approximately $16 billion) against the $3 trillion annual cost of illness, the author creates a persuasive, evidence-based argument for sustained government investment in biomedical research.
Structure breakdown
The paper opens with an overview of NIH's historical achievements and the distribution of research funding across sectors. It then shifts to critical perspectives, examining how pharmaceutical companies leverage government-funded discoveries while charging high prices. The final section applies a hypothetical lens — what if funding were cut? — to reinforce the importance of sustained federal commitment to medical research. The structure moves logically from descriptive to critical to speculative analysis.
Introduction to Federal Government Funding
Federal funding has been at the heart of many breakthroughs in medical research throughout the 20th century (Angela & Chris, 2000). The National Institutes of Health (NIH) takes credit for leading the research campaign for many decades, and its achievements have had far-reaching effects on public health and scientific advancement.
NIH Achievements and Funding Distribution
The achievements attributed to NIH are numerous and include the following (Angela & Chris, 2000):
Reduced time frames for the discovery and development of new cures; lowered incidence of disease rates among the sick; reduced mortality; reduced disability levels; better quality of life through pain reduction and the alleviation of suffering; and sustained university research, education, and the development of future leading scientists through ongoing support.
The federal government, through NIH, funds 36% of all biomedical research in the United States. Non-profit organizations contribute 7%, while the private sector funds the remaining 57% (Angela & Chris, 2000).
Although the federal government funds both basic and applied research, it has directed most of its resources toward basic research. Basic research is essential to the discovery of new scientific principles. Researchers are often unable to obtain enforceable property rights that would help them recover their investment in new ideas, and basic research disseminates knowledge freely. Consequently, investing in basic research is often unprofitable in the short run unless it has clear links to applied research (Angela & Chris, 2000).
Concerns About Federal Government Funding
The Boston Globe's Spotlight Team led a group of researchers investigating health-related R&D in the 1990s and concluded that pharmaceutical companies "piggyback" on government-funded research and in turn charge onerous prices (Wendy, 2011). The investigation found that NIH takes significant risks while reaping comparatively little in return. The Globe's report stated that government-funded research worth approximately $170 million contributes between 40% and 50% of the best-selling drugs. The net profit recovered from the sale of such drugs by companies in 1997 was 14%, which is higher than the 6% average recorded for industrial companies in the Standard & Poor index (Wendy, 2011).
The government funds basic research on the premise that the knowledge acquired constitutes a public good, and that incentives such as patents motivate companies to bring research results to the marketplace. Other observers point out, however, that health care benefits are both public and private in nature, and that it is therefore not an entirely public good (Wendy, 2011). Companies receive individual benefits that are partly determined by public investments. It has also been observed that incentives for drug development and patents do not necessarily drive innovation in the field, given the substantial degree of government subsidization of research and development (Wendy, 2011).
Conclusion
Investment in NIH remains critically underfunded relative to the scale of the problem it is meant to address. Medical advances that emerge from NIH-funded research are essential to reducing the cost of illness, combating emerging infectious diseases, and improving quality of life. Sustained federal commitment to biomedical research is not merely a fiscal choice — it is a long-term investment in public health and national well-being.
References
Angela Ritzert & Chris Edwards. (2000). The Benefits of Medical Research and the Role of the NIH.
Wendy H. Schacht. (2011). Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship.
Create your account
Always verify citation format against your institution’s current style guide requirements.